NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 1 FDA
NCT07365241 2026-01-26A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerAbbViePhase 3 Not yet recruiting531 enrolled
NCT06496048 2024-12-12Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCLuye Pharma Group Ltd.Phase 3 Recruiting180 enrolled